Guide

Will the IRA hinder the potential of Biosimilars?

Chemical chain
Chemical chain
The biosimilar marketplace in the American healthcare system has led to $21 billion in savings over the past 6 years. Since 2015, 42 biosimilars have been approved and 38 launched, driving competition and reducing prices for reference products. However, the Inflation Reduction Act (IRA) threatens this progress by discouraging biosimilar development. This undermines potential savings and hinders innovation. This issue brief outlines the efforts needed to mitigate the effects of this legislation and fully realize the benefits of biosimilars.
Chemical chain

Related resources

Webinar

Thinking ahead: How integrated development plans improve product success

Article

Insights from Pharma 2025: Patient empowerment through the European Health Data Space (EHDS)

Article

Insights from Pharma 2025: Unlocking innovation: New models and next-gen tech for success

We’re here to help

Connect with our team today to learn more about how Cencora is helping to shape the future of healthcare.

Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.

Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.